DPP4 and diabetes mellitus: Large-scale characterization of the effectiveness of type 2 diabetes therapy across nations through an open collaborative research network aligns with the 2017 recommendation of the American Association of Clinical Endocrinologists and American College of Endocrinology in type 2 diabetes management recommending dipeptidyl peptidase 4 inhibitors over sulfonylureas in patients with diabetes for whom metformin was the first-line treatment.